Povorcitinib is an investigational new drug that is being evaluated for the treatment of the skin conditions hidradenitis suppurativa[1][2] and chronic prurigo.[3][4] It is a JAK1 inhibitor.[5]
Clinical data | |
---|---|
Other names | INCB-054707 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H22F5N7O |
Molar mass | 507.469 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022 May;186(5):803-813. doi:10.1111/bjd.20969 PMID 34978076
- ^ Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi:10.1016/j.jaad.2023.10.034 PMID 37871805
- ^ "Povorcitinib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.
- ^ Thünemann J, Müller S, Steinbrink K, Ständer S, Zeidler C (June 2024). "Chronic Prurigo". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG. 22 (6): 813–823. doi:10.1111/ddg.15317. PMID 38722190.
- ^ Liao V, Cornman HL, Ma E, Kwatra SG (May 2024). "Prurigo nodularis: new insights into pathogenesis and novel therapeutics". The British Journal of Dermatology. 190 (6): 798–810. doi:10.1093/bjd/ljae052. PMC 11099982. PMID 38345154.